Patent cliff fuels Novartis’ $1.5bn swoop for London biotech
Monday 06 July 2026 6:16 pm Myricx has developed a new platform for antibody-drug conjugates Swiss pharmaceutical giant…
Switzerland leads Europe in deep tech venture capital
SOFIAH NICHOLE SALIVIO News Editor Switzerland has retained the top global ranking for the share of venture capital…
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion
Novartis NOVN -1.20%decrease; red down pointing triangle said it agreed to buy biotech company Excellergy for up to…
Novartis Earnings Hit by Generic Competition
Novartis NOVN 0.79%increase; green up pointing triangle reported a drop in earnings as generic competition for its top-selling…
Wilson Sonsini Advises Foresight on Roche Settlement and Licensing Agreement
On August 29, 2025, Foresight Diagnostics, a privately held cancer diagnostics company and CLIA-registered laboratory, announced that it…
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion
Novartis NOVN 1.69%increase; green up pointing triangle said it agreed to buy biotech company Excellergy for up to…
UK-Swiss trade deal held up over pharma row – POLITICO
The Swiss are “very angry, understandably, and [the pharmaceutical] industry are angry, because the U.K. has turned around…
Abusive pharma patents: Roche’s “mAb” empire
This summer, Roche followed the same playbook for another of its cancer drugs, Lunsumio. As of early November,…